Received Feb 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 04774 | — |
she was due for a Second dose a few months later and a third dose 6 months after that initial. She just came in for her Second dose,; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old female patient who received HAB (Twinrix) (batch number 04774) for prophylaxis. Previously administered products included Twinrix (1st dose received in Sep 2024). On 17-FEB-2025, the patient received the 2nd dose of Twinrix. On 17-FEB-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: she was due for a Second dose a few months later and a third dose 6 months after that initial. She just came in for her Second dose,). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-FEB-2025 The reporter called to inquire about a patient who they administered a Twinrix vaccine back in September, she was due for a second dose a few months later and a third dose 6 months after that initial. However she came in for her second dose late, so, they were not sure that she should come in for her third dose in a month and keep the 6 months after the 1st one or they should wait a while after the second dose. The patient received 2nd dose longer than the recommended interval, which led to lengthening of vaccination schedule.